Trailer: The Lumara Series

Filter by:

You might also like:

Episode 8: Launching Lumara

Episode 8 brings the series together with a pragmatic launch integration plan: how a specialty biologic turns strategy into day-one execution. We outline the success factors that consistently separate winners: clear, payer-oriented messaging; layered evidence with early RWE; real-time competitive response; cross-TA access innovation; and tight alignment across Access, HEOR, Medical, and Field.

Episode 7: Lessons from Elsewhere –– What Other TAs Are Doing Better

Episode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch.

Episode 6: The Unknown Unknowns

Episode 6 pulls back the curtain on competitive intelligence (CI) maturity in severe asthma launches—what top teams track, how fast they learn, and why it matters for pricing, access, messaging, and patient support. We contrast integrated, always-on CI programs with reactive, vendor-only approaches, and show how social listening, field feedback loops, KOL digital patterns, and payer advisory monitoring translate into real decisions.

Episode 5: Scaling the Access Wall

Episode 5 examines how real-world evidence (RWE) is now the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations.

Episode 4: Message Battles

In Episode 4 we'll explore how existing brands in the Severe Asthma market are positioning their value stories to payers — in both economic and clinical terms. The episode will examine the structure, tone, and content of competitor access messaging, including AMCP dossiers, value decks, and in-field conversations. Lumara’s team must develop a differentiated and credible payer narrative — one that can cut through entrenched positioning and resonate with pharmacy and medical directors.

Episode 3: Patient Support Showdown

Episode 3 zeroes in on the first-fill moment and early adherence—where HUB design, copay policy, and specialty-pharmacy handoffs can make or break momentum. We unpack the essentials of high-performing programs (benefits investigation, real-time PA tracking, FRM support, nurse case management, and digital enrollment) and spotlight where patients and offices most often stall.

Lumara Series Episode 2: The Coverage Chessboard

Episode 2 dives into the real engine of access: how plans decide who gets preferred, who gets blocked, and what it really costs to move tiers.

Lumara Series Episode 1: Meet Lumara

In Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market.

Trailer: The Lumara Series

Series Overview: The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially...

What Airbnb’s AI-First Pivot Means for Specialty Pharma

The seamless, AI-powered experiences consumers encounter in travel, retail, and entertainment shape their expectations of what healthcare support should feel like.

How AI Voice Technology Reshaped Publishing—and What It Means for Pharma.

Turning Up the Volume: How AI Voice Technology Reshaped Publishing—and What It Means for Other Industries Artificial intelligence is now...

Breaking Down Barriers: Why Pharma Must Simplify Eligibility Criteria

Patients facing cancer, autoimmune disease, or rare disorders don’t have time to spare—but too often, the very first step in their...

From Chatbots to Co-Pilots — Why Pharma Needs Agentic AI

What if your most consistent team member never got tired, forgot nothing, escalated wisely, and worked 24/7 without complaint?

Greg Johnsen
Sep 21, 2025
2 min read

Series Overview:

The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially available GenAI tooling and systems to both generate all of the underlying content and the 2-speaker (podcast format) audio files that make up each of the episodes in the series. The series follows the hypothetical launch journey of Lumara, a fictional monoclonal antibody targeting Severe Asthma with dual IL-5 and IL-13 inhibition. The podcast is designed for VP- and Director-level professionals in Market Access, Brand Strategy, HEOR, and Commercial Operations roles.

Two-fold Purpose:

1) To provide insight-rich, strategic commentary on competitive dynamics in specialty pharma — using a fictional case study to surface real-world challenges, solutions, and innovations across market access and commercialization domains.

2) To demonstrate how current, commercially available GenAI technology (ChatGPT, Eleven Labs, and Google's NotebookLM) can be leveraged to create realistic, credible, and compelling 2-speaker audio overviews for specialized, high-impact training and communication campaigns for Pharma. Audio-based, podcast-style learning assets can be especially convenient and effective in scaling learning campaigns across field organizations.

Listeners of this series will quickly see and understand how this technology can transform their own learning programs, creating a new competitive advantage in the market.

Fictional Context:

Lumara is 12 months from launch. It enters a crowded space with entrenched biologics (Dupixent, Fasenra, Nucala, Tezspire). The series follows the internal strategic discussions and market landscape assessments that inform Lumara’s pre-launch planning.

Target Audience:

VPs and Directors of Market Access, Brand Marketing, and Commercial Strategy
Field reimbursement and patient services leaders
HEOR, payer strategy, and launch planning teams

What This Series Offers:

Tactical and strategic insight across the real-world battlegrounds of access and uptake
Competitive synthesis of current Severe Asthma brands and their commercial infrastructure
Forward-looking plays for gaining edge in launch planning, payer engagement, and HCP onboarding

Episode Map:

1. Meet Lumara — Establishes Lumara’s fictional profile and frames the severe asthma competitive landscape

2. The Coverage Chessboard — Explores payer contracting, step edits, and rebating strategies

3. Patient Support Showdown — Deep dive into HUB performance, co-pay design, and onboarding friction

4. Message Battles — Analyzes what current brands are telling payers and how they frame economic value

5. Scaling the Access Wall — Explores how real-world evidence is used to win or maintain formulary position

6. The Unknown Unknowns — Benchmarks how much CI competitors are doing and how they’re doing it

7. Lessons from Elsewhere — Looks at access strategies from other TAs (oncology, migraine, rare disease) that could apply to Severe Asthma

8. Launching Lumara — Synthesizes the strategic arc and imagines what successful launch execution could look like

Strategic Intention:

This is not just a thought experiment. It’s a proof of capability — showing what current commercially available GenAI technology and state-of-the-art prompting strategies can do for real brands in real treatment areas. The Lumara Series is both an example and a blueprint for what is possible.